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A retrospective chart review of 4,925 human African 
trypanosomiasis patients treated with melarsoprol in 2001–
2003 in Equateur Nord Province of the Democratic Republic 
of Congo showed a treatment failure rate of 19.5%. This 
rate increased over the 3 years. Relapse rates were highest 
in the central part of the province.
H
uman African trypanosomiasis (HAT or sleeping sick-
ness), caused by Trypanosoma brucei gambiense, is a 
slowly progressing fatal infectious disease that affects an 
estimated 100,000 persons in Central Africa each year. In 
the meningoencephalitic or second stage, melarsoprol, an 
arsenic derivative, and eﬂ  ornithine are the only effective 
drug treatments available (1). High relapse rates for patients 
treated with melarsoprol were documented in Uganda (2,3) 
and in M’banza Congo in Angola (4). We investigated re-
cent reports about very high relapse rates from the province 
of North Equator, in the Democratic Republic of Congo 
(DRC), where the largest HAT epidemic in recent history 
occurred (5).
The Study
We reviewed the records of all patients who received 
HAT treatment in the period January 1, 2001–December 
31, 2003, in the 23 treatment centers operating in North 
Equator Province. We included only those case-patients 
who had received complete treatment with melarsoprol, 
obtained from Sanoﬁ   Aventis (Paris, France) under the 
World Health Organization donation program with 1 of the 
following regimens: 3 series of 3 injections (3.4 mg/kg) at 
7-day intervals for patients with a cerebrospinal ﬂ  uid (CSF) 
leukocyte count >20 leukocytes/mm3, or 2 series of 3 injec-
tions (3.4 mg/kg) at 7-day intervals for patients with CSF 
leukocyte counts of 5–20 leukocytes/mm3. Patients were 
asked to return for a routine follow-up visit to the HAT 
treatment center at 6, 12, 18, and 24 months after treatment 
or any time they felt unwell between visits.
Age, sex, disease stage, and results of parasitologic 
tests of the patients who experienced a relapse were record-
ed during the chart review. HAT relapse was deﬁ  ned as fol-
lows: trypanosomes found in body ﬂ  uids at any follow-up 
assessment or a CSF leukocyte count >20/mm3 and twice 
as high as the count at the previous follow-up visit. This 
case deﬁ  nition for relapse is used by the national program 
and in clinical trials (6). Patients who did not show up for 
suggested follow-up visits were not visited at home.
The relapse rate was calculated as the number of pa-
tients with HAT who experienced a relapse, divided by all 
patients who received full melarsoprol treatment during 
the study period. The study included 4,925 patients with 
second-stage parasitologically conﬁ  rmed HAT; all were 
treatment-naïve for HAT, and none had been referred by 
another center. Relapse after melarsoprol treatment was 
noted for 959 (19.5%) patients. Table 1 shows the relapse 
rate by geographic area for the years 2001, 2002, and 2003. 
The patients from the central part of the province showed 
the highest relapse rates, and the trend increased over the 3 
years (χ2 for trend 22.3, p<0.001).
Table 2 shows characteristics of the patients with a 
relapse of HAT after melarsoprol treatment. Lumbar punc-
ture was performed for 92% of patients at 6 months. This 
proportion dropped to 73% after 2 years, according to the 
annual reports for 2001–2005. Only 4.8% of patients with 
ﬁ  rst-stage illness experienced a relapse; direct evidence of 
the parasite was found in 27% of these case-patients.
Conclusions
These data show that high failure rates with melarso-
prol are no longer limited to Kasai Province in DRC. The 
HAT focus of the Equateur Nord Province does not border 
that in the Kasai Province, and given the limited contact be-
tween both provinces, resistant strains likely did not spread 
from Kasai to Equateur Nord Province.
The reported failure rate is certainly underestimated 
because some of the patients who did not return for fol-
low-up visits probably died at home or sought treatment 
elsewhere. We cannot exclude the possibility that some re-
treated patients had been reinfected. However, the trend in 
observed incidence rates in Equateur Nord Province had 
been declining since 2004, and, regardless, the incidence 
was too low to contribute substantially to the observed 
19.5% failure rate. The program used only basic parasi-
tologic conﬁ  rmation tests and none of the more sensitive 
concentration techniques, such as capillary tube centrifuga-
tion, quantitative buffy coat test, or the miniature anion-
exchange column for trypanosomiasis during the study 
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period, which explains the low proportion of relapses that 
were parasitologically conﬁ  rmed.
Melarsoprol was used on a massive and unprecedented 
scale in Equateur Nord Province from 1996 through 2005, 
when 38,945 new patients received treatment with melar-
soprol (annual reports of national program 2000 and 2005), 
so drug pressure (i.e., the use of a certain antimicrobioal 
agent potentially selecting out resistant strains) was cer-
tainly present in the region. Similarly high failure rates with 
melarsoprol in the Kasai Province led the national control 
program to introduce eﬂ  ornithine as a ﬁ  rst-line treatment 
there in 2006. The cause of these high relapse rates remains 
unclear because until now melarsoprol resistance could not 
be demonstrated in parasites in vitro or in animal models 
(5). The program used a shorter melarsoprol treatment regi-
men than that used by other countries, where 3 series of 
4 injections are used. This difference is unlikely to be an 
explanation for the high relapse rates found, however, as in 
other provinces of DRC, relapse rates with the same regi-
men remained considerably lower (e.g., a 1.4% reported 
relapse rate for Bandundu Province, according to the 2006 
Annual Report of the national control program).
Given this high failure rate, a switch to the safer ef-
lornithine regimen is the most obvious solution. However, 
this drug is more complex to administer: patients receiv-
ing it require intravenous ﬂ  uids and a high standard of 
nursing care. Eﬂ  ornithine offers the additional advantage 
of lesser toxicity, which might enhance the acceptability 
of HAT treatment. A cost-effectiveness analysis showed 
that eﬂ  ornithine is the more cost-effective option when-
ever relapse rates with melarsoprol treatment exceed 15% 
(7). Legitimate concerns have been raised regarding the 
use of this drug in monotherapy as ﬁ  rst-line treatment be-
cause there are no alternatives if resistance to it emerges. A 
clinical trial on the use of the combination DFMO (alpha-
diﬂ  uoromethylornithine)–nifurtimox is in progress (8). Our 
data show the urgent need for novel drugs for stage-2 HAT. 
Public-private partnerships such as the Drugs for Neglected 
Diseases Initiative and others are currently investing in de-
velopment of such drugs, but a new drug will not likely 
be available within the next decade. Therefore, rapidly 
controlling new outbreaks is essential to prevent large epi-
demics. These outbreaks may be more difﬁ  cult to control if 
eﬂ  ornithine resistance emerges.
Dr Robays is currently working for the Epidemiology and Dis-
ease Control Unit of the Institute of Tropical Medicine in Antwerp. 
His research focus is effective control and surveillance of HAT.
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Table 1. Melarsoprol relapse rates in second-stage human African trypanosomiasis patients, Equateur Nord Province, 2001–2003 
Part of province 
Northern Central Southern Total 
Year  No. treated 
No. (%) 
relapsed No. treated 
No. (%) 
relapsed No. treated 
No. (%) 
relapsed No. treated 
No. (%) 
relapsed
2001 708 90 (12.7)  1,154 284 (24.6)  506 46 (9.1)  2,368 420 (17.7) 
2002 572 56 (9.8)  799 180 (22.5)  135 36 (26.7)  1,506 272 (18.1) 
2003 362 57 (15.7)  570 171 (30.0)  119 39 (32.8)  1,051 267 (25.4) 
Total 1,642 203 (12.4)  2,523 635 (25.2)  760 121 (15.9)  4,925 959 (19.5) 
Table 2. Characteristics of 959 patients who experienced relapse 
after treatment with melarsoprol, Equateur Nord Province,  
2001–2003
Characteristic No. (%) 
Sex 
 M  433  (45.2) 
 F  526  (54.8) 
Age
  >1–11 mo  1 (0.1) 
  12–59 mo  13 (1.4) 
   5–59 y  936 (97.6) 
>60 y  9 (0.9) 
Stage of disease 
 First  46  (4.8) 
  Second   782 (81.5) 
 Unknown  131  (13.7) 
Parasites found  259 (27.0) 